KLK3 and prostate carcinoma: Enzalutamide-containing treatment was also associated with a significantly reduced risk of most secondary endpoints including time to prostate-specific antigen (PSA) progression (HR 0.44, 95% CI 0.38–0.52), time to clinical progression (HR 0.45, 95% CI 0.39–0.53), and prostate cancer-specific survival (HR 0.67, 95% CI 0.54–0.82) (14).